test

Vorinostat in Combination With Palliative Radiotherapy for Patients With Non-Small Cell Lung Cancer

Conditions

Non-Small Cell Lung Cancer (NSCLC)

What is the purpose of this trial?


This is a dose escalation study that will assess the safety of Vorinostat, a Histone
Deacetylase (HDAC) inhibitor, in combination with palliative radiotherapy in patients with
advanced or metastatic Non-Small Cell Lung Cancer (NSCLC). Vorinostat has been approved for
use in patients with cutaneous T-cell lymphomas, but several pre-clinical studies suggest
activity in lung cancer cell lines. Several HDAC inhibitors,including Vorinostat, may
enhance the effect of radiotherapy, and this study will seek to confirm this.

Participation Guidelines

Age:
18 Years - N/A
Gender:
Both

Click here for detailed information about who can participate in this trial.


Sponsor:
Merck Sharp & Dohme Corp.
Yale University
Dates:
May 2009
Last Updated:
December 7, 2012
Study HIC#:

Clinicaltrials.gov ID: NCT00821951